MediciNova 8-K 2013
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2013
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (858) 373-1500
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On May 9, 2013 (Japanese Standard Time), MediciNova, Inc. (the Company) filed with the Osaka Securities Exchange a Japanese report referred to as Kessan Tanshin, which contained the Companys financial results for the quarter ended March 31, 2013 (the Tanshin).
The Tanshin is substantially the same as the Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, except the following supplemental information is provided:
Note to financial results forecast: The above estimates are based on certain assumptions made by the Companys management as of the date hereof. These assumptions are based on managements experience and perception of current conditions, trends, expected future developments and other factors believed to be appropriate in the circumstances. Such estimates are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company and may cause the Companys actual results to differ materially from the above estimates. Although the Companys management believes that these assumptions are reasonable, the Company cannot assure you that the Companys business will develop in accordance with these estimates. Investors are cautioned not to rely on these estimates as it is highly likely that actual results will differ, perhaps materially. These risks include the risk factors detailed in the Companys Securities and Exchange Commission filings, including the Companys Annual Report on Form 10-K for the year ended December 31, 2012. Our independent auditors have not compiled or been involved in the preparation of the forecasted financial results for fiscal year 2013. Accordingly, they assume no responsibility for the accuracy or presentation of this information.
The information in this Current Report is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The Tanshin may contain forward-looking statements that are subject to risks and uncertainties, many of which are beyond the Companys control. Forward-looking statements discuss matters that are not historical facts. The Companys actual results may differ from those expressed or implied in these forward-looking statements as a result of various factors, including those set forth in the Companys Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission on March 28, 2013 and its subsequent periodic reports on Forms 10-Q and 8-K, and the differences may be material. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements, include, but are not limited to, risks and uncertainties inherent in clinical trials, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom the Company relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities, the timing of expected filings with the regulatory authorities, risks relating to the completion of the joint venture in China, the Companys collaborations with third parties, the availability of funds to complete product development plans and the Companys ability to raise sufficient capital when needed. These forward-looking statements may be preceded by, followed by or otherwise include the words believes, expects, forecasts, anticipates, intends, estimates, projects, can, could, may, will, would or similar expressions. For such statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update publicly or revise any forward-looking statements set forth in the Tanshin, whether as a result of new information, future events or otherwise, unless required by law.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 9, 2013